drugset / Trial / NCT07013201

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201

Phase 2 Recruiting 135 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.

Timeline

Start
2025-09-11
Primary completion
2026-12-14
Completion
2026-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Delgocitinib Small molecule 20 unknown Topical